Just a reminder, RAC initiated a P2 Zan + Inqovi EMD AML trial that should have been completed this year. The market is so niche that they couldn't dose a patient.
And that's after the trial was expanded to Europe.
IMO, If the Company announced that any unexercised bonus (and subsequent piggyback) option were to be purged, the SP would immediately rally as a result of those looking to pick up the shortfall buying on market.
A further raise for an expanded basket trial could be undertaken if/when CPACS is validated in Zan + Dox - or funded via a third party.
Ann: Application for quotation of securities - RAC, page-15
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.000(0.00%) |
Mkt cap ! $281.1M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.66 | $1.61 | $117.0K | 71.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12252 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 900 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |